David Steinberg
Stock Analyst at Jefferies
(2.93)
# 1,672
Out of 5,090 analysts
33
Total ratings
64%
Success rate
26.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Steinberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHC Bausch Health Companies | Downgrades: Hold | $12 → $8 | $6.93 | +15.44% | 7 | Feb 6, 2025 | |
| PRGO Perrigo Company | Upgrades: Buy | $45 → $63 | $13.44 | +368.75% | 8 | Sep 30, 2021 | |
| SUPN Supernus Pharmaceuticals | Upgrades: Buy | $25 → $40 | $45.68 | -12.43% | 11 | Apr 13, 2021 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $151 → $188 | $169.70 | +10.78% | 5 | Oct 9, 2020 | |
| OCUL Ocular Therapeutix | Initiates: Buy | $8 | $12.58 | -36.41% | 1 | Mar 17, 2020 | |
| SVRA Savara | Initiates: Buy | $20 | $6.50 | +207.69% | 1 | Sep 22, 2017 |
Bausch Health Companies
Feb 6, 2025
Downgrades: Hold
Price Target: $12 → $8
Current: $6.93
Upside: +15.44%
Perrigo Company
Sep 30, 2021
Upgrades: Buy
Price Target: $45 → $63
Current: $13.44
Upside: +368.75%
Supernus Pharmaceuticals
Apr 13, 2021
Upgrades: Buy
Price Target: $25 → $40
Current: $45.68
Upside: -12.43%
Jazz Pharmaceuticals
Oct 9, 2020
Maintains: Buy
Price Target: $151 → $188
Current: $169.70
Upside: +10.78%
Ocular Therapeutix
Mar 17, 2020
Initiates: Buy
Price Target: $8
Current: $12.58
Upside: -36.41%
Savara
Sep 22, 2017
Initiates: Buy
Price Target: $20
Current: $6.50
Upside: +207.69%